TB Diagnostic Market is estimated to increase at a growth rate of 6.2% CAGR over the forecast period from 2024 to 2030.
The global TB Diagnostic Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Test (Radiographic Test, Laboratory Test, Nucleic Acid Testing, Cytokine Detection Test, Drug Resistance Test, Others), By End-User (Hospitals, Clinics, Diagnostics Laboratories, Others).
An Introduction to TB Diagnostic Market in 2024
The TB Diagnostic Market includes tuberculosis (TB) diagnostic tests, molecular assays, serological tests, chest X-rays, and sputum microscopy used for TB screening, TB infection detection, and TB disease diagnosis in healthcare settings, public health laboratories, and TB control programs. TB diagnostic methods detect Mycobacterium tuberculosis bacteria, TB antibodies, or TB biomarkers in patient samples to confirm TB infection, assess disease severity, and guide TB treatment strategies. Market trends focus on rapid TB diagnostic kits, point-of-care TB testing devices, TB culture systems, and automated TB diagnostic platforms for timely TB diagnosis, drug susceptibility testing, and TB surveillance in global TB control efforts.
TB Diagnostic Market Competitive Landscape
The global TB Diagnostic Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, TB Diagnostic Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the TB Diagnostic Industry include- Abbott Laboratories, AdvaCare Pharma, Becton, Dickinson and Company, BioMerieux SA, Cepheid, F. Hoffmann-La Roche Ltd, Hain Lifescience GmbH, Hologic Corp, Qiagen NV, Thermo Fisher Scientific Inc.
TB diagnostic Market Trend: Advancements in Diagnostic Technologies
The TB diagnostic market is experiencing a trend towards advancements in diagnostic technologies. With tuberculosis remaining a global health threat, there's a growing emphasis on developing rapid, accurate, and point-of-care diagnostic tests to improve disease detection and management. This trend is driven by the need for timely diagnosis, especially in resource-limited settings, and the growing recognition of drug-resistant TB strains, necessitating more sensitive and specific diagnostic tools.
TB diagnostic Market Driver: High Global Burden of Tuberculosis
The primary driver for the TB diagnostic market is the high global burden of tuberculosis and the urgent need for effective disease control measures. Tuberculosis continues to be a leading cause of morbidity and mortality worldwide, particularly in low- and middle-income countries with limited access to healthcare resources. The increasing incidence of drug-resistant TB strains further underscores the importance of accurate and timely diagnosis for appropriate treatment and infection control efforts.
TB diagnostic Market Opportunity: Expansion of Point-of-Care Testing Solutions
An opportunity exists in the expansion of point-of-care testing solutions for tuberculosis diagnosis. With the decentralization of healthcare services and the growing demand for rapid diagnostic tests that can be performed closer to the patient, there's a need for portable, user-friendly, and cost-effective TB diagnostic devices. Companies investing in the development of innovative point-of-care TB tests, leveraging technologies such as molecular diagnostics, nucleic acid amplification, and rapid antigen detection, can capitalize on the opportunity to address unmet diagnostic needs and improve patient outcomes.
TB Diagnostic Market Share Analysis: Nucleic Acid Testing is the fastest growing market segment over the forecast period to 2030
Among the segmented categories, Nucleic Acid Testing (NAT) emerges as the fast-growing test in the market for tuberculosis (TB) diagnostics. NAT represents a cutting-edge molecular diagnostic technique that allows for the direct detection of Mycobacterium tuberculosis (MTB) DNA or RNA in clinical specimens such as sputum, blood, or urine. This method offers several advantages over traditional laboratory tests and radiographic imaging, including high sensitivity and specificity, rapid turnaround time, and the ability to detect drug-resistant strains of TB. As the global burden of TB remains substantial and the emergence of drug-resistant TB strains poses a significant public health challenge, the demand for accurate and timely diagnostic tools has intensified. NAT meets these demands by providing healthcare professionals with a reliable means of early detection and effective management of TB, leading to improved patient outcomes and reduced transmission rates. With increasing investments in TB control programs and the adoption of molecular diagnostic technologies in healthcare settings worldwide, the market for NAT in TB diagnostics is poised for rapid growth in the coming years.
TB Diagnostic Market Segmentation
By Test
Radiographic Test
Laboratory Test
Nucleic Acid Testing
Cytokine Detection Test
Drug Resistance Test
Others
By End-User
Hospitals
Clinics
Diagnostics Laboratories
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
TB Diagnostic Companies
Abbott Laboratories
AdvaCare Pharma
Becton, Dickinson and Company
BioMerieux SA
Cepheid
F. Hoffmann-La Roche Ltd
Hain Lifescience GmbH
Hologic Corp
Qiagen NV
Thermo Fisher Scientific Inc
* List not Exhaustive
Reasons to Buy the TB Diagnostic Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the TB Diagnostic Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the TB Diagnostic Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 TB Diagnostic Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global TB Diagnostic Market Size Outlook, $ Million, 2021 to 2030
3.2 TB Diagnostic Market Outlook by Type, $ Million, 2021 to 2030
3.3 TB Diagnostic Market Outlook by Product, $ Million, 2021 to 2030
3.4 TB Diagnostic Market Outlook by Application, $ Million, 2021 to 2030
3.5 TB Diagnostic Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of TB Diagnostic Industry
4.2 Key Market Trends in TB Diagnostic Industry
4.3 Potential Opportunities in TB Diagnostic Industry
4.4 Key Challenges in TB Diagnostic Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global TB Diagnostic Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global TB Diagnostic Market Outlook by Segments
7.1 TB Diagnostic Market Outlook by Segments, $ Million, 2021- 2030
By Test
Radiographic Test
Laboratory Test
Nucleic Acid Testing
Cytokine Detection Test
Drug Resistance Test
Others
By End-User
Hospitals
Clinics
Diagnostics Laboratories
Others
8 North America TB Diagnostic Market Analysis and Outlook To 2030
8.1 Introduction to North America TB Diagnostic Markets in 2024
8.2 North America TB Diagnostic Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America TB Diagnostic Market size Outlook by Segments, 2021-2030
By Test
Radiographic Test
Laboratory Test
Nucleic Acid Testing
Cytokine Detection Test
Drug Resistance Test
Others
By End-User
Hospitals
Clinics
Diagnostics Laboratories
Others
9 Europe TB Diagnostic Market Analysis and Outlook To 2030
9.1 Introduction to Europe TB Diagnostic Markets in 2024
9.2 Europe TB Diagnostic Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe TB Diagnostic Market Size Outlook by Segments, 2021-2030
By Test
Radiographic Test
Laboratory Test
Nucleic Acid Testing
Cytokine Detection Test
Drug Resistance Test
Others
By End-User
Hospitals
Clinics
Diagnostics Laboratories
Others
10 Asia Pacific TB Diagnostic Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific TB Diagnostic Markets in 2024
10.2 Asia Pacific TB Diagnostic Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific TB Diagnostic Market size Outlook by Segments, 2021-2030
By Test
Radiographic Test
Laboratory Test
Nucleic Acid Testing
Cytokine Detection Test
Drug Resistance Test
Others
By End-User
Hospitals
Clinics
Diagnostics Laboratories
Others
11 South America TB Diagnostic Market Analysis and Outlook To 2030
11.1 Introduction to South America TB Diagnostic Markets in 2024
11.2 South America TB Diagnostic Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America TB Diagnostic Market size Outlook by Segments, 2021-2030
By Test
Radiographic Test
Laboratory Test
Nucleic Acid Testing
Cytokine Detection Test
Drug Resistance Test
Others
By End-User
Hospitals
Clinics
Diagnostics Laboratories
Others
12 Middle East and Africa TB Diagnostic Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa TB Diagnostic Markets in 2024
12.2 Middle East and Africa TB Diagnostic Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa TB Diagnostic Market size Outlook by Segments, 2021-2030
By Test
Radiographic Test
Laboratory Test
Nucleic Acid Testing
Cytokine Detection Test
Drug Resistance Test
Others
By End-User
Hospitals
Clinics
Diagnostics Laboratories
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
AdvaCare Pharma
Becton, Dickinson and Company
BioMerieux SA
Cepheid
F. Hoffmann-La Roche Ltd
Hain Lifescience GmbH
Hologic Corp
Qiagen NV
Thermo Fisher Scientific Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
